Amy King, APRN
Adult Health · Lincoln, NENPI 1821737719
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,892 of the $6,722 with a category attached, or 72.8%. 33 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 43.9% of the total. Reporting peaked in 2024 at $3,272 and has fallen 54.5% since, to $1,489 in 2025. Among adult health clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $33.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- AstraZeneca$631
- Sanofi-aventis U.S. LLC$377
- Boehringer Ingelheim$374
- Grifols USA, LLC$329
- Harmony Biosciences LLC$281
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,12517%
- Food & beverage$4,89273%
- Education$70510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 57 | $2,953 |
| AstraZeneca | 10 | $631 |
| Sanofi-aventis U.S. LLC | 4 | $377 |
| Boehringer Ingelheim | 18 | $374 |
| Grifols USA, LLC | 14 | $329 |
| Harmony Biosciences LLC | 13 | $281 |
| Jazz Pharmaceuticals Inc. | 9 | $275 |
| Sanofi | 13 | $207 |
| Amgen | 11 | $204 |
| Astellas Pharma US Inc | 3 | $180 |
| United Therapeutics Corporation | 3 | $99 |
| Regeneron Healthcare Solutions, Inc. | 5 | $82 |
| Actelion Pharmaceuticals US, Inc. | 5 | $78 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Resmed Corp | 1 | $48 |
| Electromed, Inc. | 6 | $47 |
| GSK | 3 | $46 |
| Baxter Healthcare | 2 | $44 |
| Verona Pharma, Inc. | 2 | $37 |
| Tactile Systems Technology Inc | 1 | $35 |
| AbbVie | 2 | $32 |
| Philips North America LLC | 2 | $30 |
| Genentech, Inc. | 1 | $30 |
| Insmed, Inc. | 2 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $28 |
| Johnson & Johnson | 2 | $26 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Hospira, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,722 in reported general payments places this provider in the 95th percentile of 58 adult health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $131,092 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 141 | $92,761 |
| Dupixent PenDupilumab | 21 | $88,559 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $48,982 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $40,406 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $39,062 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $24,942 |
| Spiriva RespimatTiotropium Bromide | 24 | $22,908 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $13,143 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $12,839 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $5,504 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,976 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $4,427 |
| DuleraMometasone/Formoterol | 11 | $4,144 |
| Ventolin HfaAlbuterol Sulfate | 27 | $1,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $46 | $231,974369 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $631 | $105,904191 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat | $374 | $88,256115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 adult health providers in Nebraska.
Other adult health in Lincoln
- Heather MosleyLincoln$6K
- Korinne MurcekLincoln$4K
- Stacy SveenLincoln$3K
- Mary BaxterLincoln$3K
- Shirley Mohr-BurtLincoln$2K
- Jessica MattisonLincoln$2K
- Kelly FieldsLincoln$2K
- Thien KieuLincoln$2K
- Lauren KellyLincoln$1K
- Rhonda OlmstedLincoln$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.